| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2010-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013513370-A |
| titleOfInvention |
Trispecific therapeutic agent for acute myeloid leukemia |
| abstract |
The present invention relates to molecules having binding specificity for (a) CD123; (b) CD16 and (c) CD33. The invention further includes a first immunoglobulin domain (this immunoglobulin domain specifically binds to CD123) containing a V L domain linked to a V H domain; including V L domain linked to a V H domain the second immunoglobulin domain (this immunoglobulin domain specifically binds to CD16); and a third immunoglobulin domain comprising a V L domain linked to a V H domain (specific for the immunoglobulin domain CD33 To the molecule of the present invention. The invention further relates to nucleic acid molecules that encode the molecules of the invention. The present invention further relates to diagnostic and pharmaceutical compositions and uses of the molecules or nucleic acid molecules of the present invention in the treatment of acute myeloid leukemia and / or myelodysplastic syndrome. [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019151647-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018531939-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017519502-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016520569-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11492408-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7274781-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11098100-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11098101-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018504145-A |
| priorityDate |
2009-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |